CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cryoport, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.98+0.14 (+0.83%)
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.86 (+67.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Cryoport, Inc. grew revenue 12.1% to $186.45M over the twelve months to Jun 30, 2026. Free cash flow was -$20.03M.
Revenue
$186.45M
+12.1% vs. a year earlier
Operating income
-$39.62M
TTM Q2 2026
Free cash flow
-$20.03M
TTM Q2 2026
EPS, diluted
-$0.90
-163.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $856.52M
- P/E ratio
- –
- Price to sales
- 4.59
- Price to book
- 1.75
- Dividend yield
- –
- Free cash flow yield
- -2.34%
Fundamentals
- Revenue
- $186.45M
- Net income
- -$37.39M
- EPS, diluted
- -$0.90
- Free cash flow
- -$20.03M
- Book value per share
- $9.73
- Diluted shares
- 50M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$186.45M+12.1% YoY
Gross profit
$87.77M+14.1% YoY
Operating income
-$39.62M
Net income
-$37.39M-147.3% YoY
EPS, diluted
-$0.90-163.8% YoY
Free cash flow
-$20.03M
Reported periodTrailing twelve months